In addition to SN38‐induced cancer death by inhibiting DNA replication, we hypothesized that simultaneous targeting of COX‐2 and VEGF pathways might improve the antiangiogenic activity after SN38‐Nif prodrug conversion. This evidence concerns the gene VEGFA and cancer.